gsk plc - GSK

GSK

Close Chg Chg %
52.07 0.32 0.60%

Closed Market

52.39

+0.32 (0.60%)

Volume: 3.99M

Last Updated:

Mar 19, 2026, 3:59 PM EDT

Company Overview: gsk plc - GSK

GSK Key Data

Open

$51.76

Day Range

51.65 - 52.69

52 Week Range

32.38 - 61.70

Market Cap

$104.21B

Shares Outstanding

2.00B

Public Float

2.00B

Beta

0.46

Rev. Per Employee

N/A

P/E Ratio

14.00

EPS

$3.72

Yield

336.81%

Dividend

$0.48

EX-DIVIDEND DATE

Feb 20, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

5.18M

 

GSK Performance

1 Week
 
-2.49%
 
1 Month
 
-12.53%
 
3 Months
 
7.10%
 
1 Year
 
32.67%
 
5 Years
 
42.12%
 

GSK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About gsk plc - GSK

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK At a Glance

GSK Plc
79 New Oxford Street
London, Greater London WC1A 1DG
Phone 44-20-8047-5000 Revenue 43.05B
Industry Pharmaceuticals: Major Net Income 7.53B
Sector Health Technology 2025 Sales Growth 7.38%
Fiscal Year-end 12 / 2026 Employees 66,841
View SEC Filings

GSK Valuation

P/E Current 13.998
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 13.186
Price to Sales Ratio 2.345
Price to Book Ratio 4.467
Price to Cash Flow Ratio 10.49
Enterprise Value to EBITDA 8.619
Enterprise Value to Sales 2.779
Total Debt to Enterprise Value 0.199

GSK Efficiency

Revenue/Employee 644,088.526
Income Per Employee 112,701.197
Receivables Turnover 4.341
Total Asset Turnover 0.55

GSK Liquidity

Current Ratio 0.819
Quick Ratio 0.542
Cash Ratio 0.159

GSK Profitability

Gross Margin 71.46
Operating Margin 25.157
Pretax Margin 22.653
Net Margin 17.498
Return on Assets 9.616
Return on Equity 38.484
Return on Total Capital 16.425
Return on Invested Capital 19.50

GSK Capital Structure

Total Debt to Total Equity 108.201
Total Debt to Total Capital 51.969
Total Debt to Total Assets 28.993
Long-Term Debt to Equity 89.809
Long-Term Debt to Total Capital 43.136
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Gsk Plc - GSK

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
36.12B 37.70B 40.09B 43.05B
Sales Growth
-23.01% +4.37% +6.35% +7.38%
Cost of Goods Sold (COGS) incl D&A
12.15B 11.28B 12.11B 12.29B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
2.64B 2.85B 3.26B 3.05B
Depreciation
1.31B 1.34B 1.40B 1.39B
Amortization of Intangibles
1.34B 1.51B 1.86B 1.66B
COGS Growth
-25.21% -7.13% +7.33% +1.47%
Gross Income
23.97B 26.42B 27.98B 30.76B
Gross Income Growth
-21.85% +10.20% +5.93% +9.94%
Gross Profit Margin
+66.37% +70.07% +69.80% +71.46%
2022 2023 2024 2025 5-year trend
SG&A Expense
15.74B 17.72B 20.75B 19.93B
Research & Development
5.96B 6.52B 7.02B 8.17B
Other SG&A
9.79B 11.20B 13.72B 11.76B
SGA Growth
-23.20% +12.59% +17.06% -3.93%
Other Operating Expense
- - - -
-
Unusual Expense
2.93B 1.78B 3.15B 2.11B
EBIT after Unusual Expense
5.30B 6.92B 4.08B 8.72B
Non Operating Income/Expense
2.68B 1.59B 1.19B 1.91B
Non-Operating Interest Income
78.83M 68.37M 84.34M 83.03M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.05B 963.37M 822.91M 879.03M
Interest Expense Growth
-2.17% -8.21% -14.58% +6.82%
Gross Interest Expense
1.05B 963.37M 822.91M 879.03M
Interest Capitalized
- - - -
-
Pretax Income
6.93B 7.54B 4.45B 9.75B
Pretax Income Growth
-6.78% +8.78% -41.06% +119.31%
Pretax Margin
+19.20% +20.01% +11.09% +22.65%
Income Tax
870.87M 939.75M 672.13M 1.47B
Income Tax - Current - Domestic
1.84B 2.01B 1.98B 1.84B
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(965.72M) (1.08B) (1.31B) (372.96M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
6.06B 6.60B 3.77B 8.29B
Minority Interest Expense
566.62M 472.36M 480.46M 755.15M
Net Income
5.49B 6.13B 3.29B 7.53B
Net Income Growth
-8.88% +11.48% -46.29% +128.94%
Net Margin Growth
+15.21% +16.25% +8.21% +17.50%
Extraordinaries & Discontinued Operations
- - - 12.93B
-
Discontinued Operations
- - - 12.93B
-
Net Income After Extraordinaries
18.42B 6.13B 3.29B 7.53B
Preferred Dividends
- - - -
-
Net Income Available to Common
18.42B 6.13B 3.29B 7.53B
EPS (Basic)
9.1518 3.0236 1.6141 3.7191
EPS (Basic) Growth
+203.69% -66.96% -46.62% +130.41%
Basic Shares Outstanding
2.01B 2.03B 2.04B 2.03B
EPS (Diluted)
9.0218 2.9802 1.5888 3.6595
EPS (Diluted) Growth
+203.08% -66.97% -46.69% +130.33%
Diluted Shares Outstanding
2.04B 2.06B 2.07B 2.06B
EBITDA
10.88B 11.54B 10.49B 13.88B
EBITDA Growth
-19.11% +6.15% -9.09% +32.26%
EBITDA Margin
+30.11% +30.62% +26.18% +32.24%

Snapshot

Average Recommendation HOLD Average Target Price 56.10
Number of Ratings 7 Current Quarters Estimate 1.171
FY Report Date 03 / 2026 Current Year's Estimate 4.805
Last Quarter’s Earnings 0.697 Median PE on CY Estimate N/A
Year Ago Earnings 4.701 Next Fiscal Year Estimate 5.294
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 17 17
Mean Estimate 1.17 1.24 4.80 5.29
High Estimates 1.24 1.37 4.97 5.84
Low Estimate 1.11 1.14 4.59 4.95
Coefficient of Variance 4.28 6.99 2.22 4.98

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 1 1 1
OVERWEIGHT 2 2 2
HOLD 3 3 3
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Hold Hold Hold

Gsk Plc in the News